A new study from JAMA shows patients using the injectable medication tirzepatide saw a 14% regain of weight one year after getting off the drug. Tirzepatide’s brand name is Zepbound.
The creators of Zepbound, Eli Lilly, sponsored the trial.
The study followed nearly 700 overweight and obese adults who the took the injectable medication for nine months. Half of those participants then switched to a placebo shot.
Over the next year, those who took Zepbound continued to lose weight, averaging about 60 pounds lost.Β Those taking the placebo shot the second part of the trial lost an average of 22 pounds from their original weight.
The author of the study says those on the placebo shot would likely continue to regain the weight they lost.
